{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:36:12Z","timestamp":1773297372404,"version":"3.50.1"},"reference-count":49,"publisher":"Informa UK Limited","issue":"sup3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2003,11,1]]},"DOI":"10.1080\/10428190310001623685","type":"journal-article","created":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T16:59:00Z","timestamp":1072803540000},"page":"S107-S113","source":"Crossref","is-referenced-by-count":14,"title":["ABCs of Radioisotopes Used for Radioimmunotherapy: \u03b1- and \u03b2-Emitters"],"prefix":"10.1080","volume":"44","author":[{"given":"Thomas","family":"Waldmann","sequence":"first","affiliation":[{"name":"National Institutes of Health, National Cancer Institute, Bldg 10, Room 4N115, 10 Center Drive 1374, Bethesda, MD, 20892-1374, USA"}]}],"member":"301","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"CIT0003","first-page":"95, 3052 \u2014 3056","author":"Hainsworth J.D.","year":"2000","journal-title":"Blood"},{"key":"CIT0004","first-page":"101 \u2014 106","volume":"97","author":"Colombat P.","year":"2001","journal-title":"clinical and molecular evaluation\", Blood"},{"key":"CIT0005","unstructured":"Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Klippenstein, D., Loud, P., et al. (2001) \"Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report\", Blood, 98, 601a [abstract 2518]."},{"key":"CIT0006","first-page":"17, 268 \u2014276","author":"Czuczman M.S","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2535"},{"key":"CIT0008","first-page":"20, 3545 \u2014 3557","author":"Dillman R.O","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"CIT0010","first-page":"3262","volume":"20","author":"Witzig T.E.","year":"2002","journal-title":"\"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma\", Journal of Clinical Oncology"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"CIT0013","first-page":"1259","volume":"96","author":"Kaminski M.S.","year":"2000","journal-title":"updated results and long-term follow-up of the University of Michigan experience\", Blood"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1316"},{"key":"CIT0015","unstructured":"Horning, S.J., Lucas, J.B., Younes, A., Podoloff, D., Jain, V., Kroll, S., et al. (2000) \"Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multicenter phase II study\", Blood, 96, 508a [abstract 2184]."},{"key":"CIT0016","unstructured":"Kaminski, M.S., Gribben, T., Estes, J., Ross, C.W., Regan, D., Zasadnyk, K., et al. (1998) \"1-131 anti-B! antibody for previously untreated follicular lymphoma (FL): clinical and molecular remis-sions\", Proceedings of the American Society for Clinical Oncology, 17, 2a [abstract]."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"CIT0018","unstructured":"Davis, T.A., Kaminski, M.S., Leonard, J.P., Gregory, S.A., Wahl, R., Hsu, F.Y., et al. (2001) \"Results of a randomized trial of Bexxar (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapse or refractory low-grade or transformed non-Hodgkin's lymphoma\", Blood, 98, 843a [abstract 3503]."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34878"},{"key":"CIT0020","first-page":"149","volume":"24","author":"Strauchen J.A","year":"1989","journal-title":"relevance to diagnosis, biology, and therapy\", Pathology Annual"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Morris, J.C. and Waldmann, T.A. (2000) \"Advances in interleukin 2 receptor targeted treatment\", Annals of Rheumatic Diseases, 59(Suppl. I), i109 \u2014i114.","DOI":"10.1136\/ard.59.suppl_1.i109"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111992"},{"key":"CIT0023","first-page":"1292","volume":"126","author":"Uchiyama T.","year":"1981","journal-title":"production of anti-Tac monoclonal antibody and distribution of Tac(+ ) cells\", Journal of Immunology"},{"key":"CIT0024","first-page":"1711","volume":"73","author":"Waldmann T.A.","year":"1984","journal-title":"monoclonal antibody identifying the human receptor for T cell growth factor\", Journal of Clinical Investigation"},{"key":"CIT0025","first-page":"481","volume":"80","author":"Uchiyama T.","year":"1977","journal-title":"clinical and hematologic features of 16 cases\", Blood"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.3.1887"},{"key":"CIT0027","first-page":"255","volume":"54","author":"Madeleine M.M.","year":"1993","journal-title":"reanalysis of 4,832 immunoblot results\", International Journal of Cancer"},{"key":"CIT0028","first-page":"428","volume":"7","author":"Shimoyama M","year":"1991","journal-title":"a report from the Lymphoma Study Group (1984-87)\", British Journal of Haematology"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"CIT0030","first-page":"6977","author":"Phillips K.E.","year":"2000","journal-title":"Cancer Research"},{"key":"CIT0031","first-page":"315 \u2014 341","volume":"17","author":"Cassidy J.","year":"1993","journal-title":"\"Pharmacolci-netics of high molecular weight agents\", Cancer Surveys"},{"key":"CIT0032","unstructured":"Knox, Si. (1995) \"Overview of studies on experimental radio-immunotherapy\", Cancer Research, 55, 5832s\u2014 5835s."},{"key":"CIT0033","first-page":"406","author":"Axworthy D.B.","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"CIT0034","unstructured":"Yao, Z., Zhang, M., Axworthy, D.B., Garmestani, K., Park, L., Park, C.W., et al. (2002) \"Radioimmunotherapy of A431 xeno-grafted mice with pretargeted B3 antibody-streptavidin and 90Y- labeled1,4,7,10-tetra-azacyclododecane-N,N',\/V\",Ar-tetra-aceticacid (DOTA)-biotin\", Cancer Research, 62, 5755\u20135760."},{"key":"CIT0035","first-page":"208","volume":"100","author":"Zhang M.","year":"2002","journal-title":"\"Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the a-emitting radio-nuclide\", Blood"},{"key":"CIT0036","first-page":"16, 109 \u2014 123","author":"Goshorn S.","year":"2001","journal-title":"Cancer Biotherapy and Radiopharmacology"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2000.15.15"},{"key":"CIT0038","unstructured":"Fritzberg, AR. (1998) \"Antibody pretargeted radiotherapy: a new approach and a second chance\", Journal of Nuclear Medicine, 39, 20N \u2014 22N."},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"CIT0040","first-page":"391 \u2014398","volume":"101","author":"Cheson B.D","year":"2003","journal-title":"\"Radioimmunotherapy of non-Hodgkin lymphomas\", Blood"},{"key":"CIT0041","first-page":"2123","author":"Press","year":"1996","journal-title":"Cancer Research"},{"key":"CIT0042","first-page":"143","volume":"134","author":"Humm J.L.","year":"1993","journal-title":"\"A model of cell inactivation by alpha-particle internal emitters\", Radiation Research"},{"key":"CIT0043","first-page":"166","volume":"40","author":"Nikula T.K.","year":"1999","journal-title":"pharmacokinetics, bioactivity, toxicity and chemistry\", Journal of Nuclear Medicine"},{"key":"CIT0044","first-page":"1537","volume":"294","author":"McDevitt MR.","year":"2001","journal-title":"\"Tumor therapy with targeted atomic nanogenerators\", Science"},{"key":"CIT0045","first-page":"1024","volume":"240","author":"Macklis R.M.","year":"1988","journal-title":"\"Radioimmunotherapy with alpha-particle-emitting immunoconjugates\", Science"},{"key":"CIT0046","first-page":"1341 \u20141351","volume":"25","author":"McDevitt MR.","year":"1998","journal-title":"\"Radioimmunotherapy with alpha-emitting nuclides\", European Journal of Nuclear Medicine"},{"key":"CIT0047","first-page":"4362","author":"Hartmann F.","year":"1994","journal-title":"Cancer Research"},{"key":"CIT0048","first-page":"1944","author":"Horak E.","year":"1997","journal-title":"Journal of Nuclear Medicine"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437788100"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190310001623685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T16:09:26Z","timestamp":1670861366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190310001623685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,1]]},"references-count":49,"journal-issue":{"issue":"sup3","published-print":{"date-parts":[[2003,11,1]]}},"alternative-id":["10.1080\/10428190310001623685"],"URL":"https:\/\/doi.org\/10.1080\/10428190310001623685","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,1]]}}}